Biotech IPO candidate

Cancer drug manufacturer gears up for HK IPO

Chinese precision medicine developer 3D Medicines wants to complete its Series A funding before it looks at an IPO in Hong Kong next year.

The race to develop medicines that target cancer has become more competitive, but it is one that has mostly been welcomed by the capital markets.

Chinese precision medicine developer 3D Medicines, also called 3DMed, is in the process of a $60 million Series A fundraising for its cancer drug research business.

In an exclusive interview with FinanceAsia, John Gong, chief executive of 3DMed, said that the company aims to complete another round of pre-IPO funding by the end of the year. And with around $150 million funding under its belt, it is looking to IPO in Hong Kong in the second or third quarter of...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222